Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2002

View Archived Issues

Lilly and EFSD announce diabetes research partnership

Ferring describes SAR leading to low-molecular-weight hK1 inhibitors

CAT offers pipeline progress report

Frovatriptan is highly effective in prophylaxis of menstrually associated migraine

Watson resubmits Oxytrol NDA for overactive bladder

New data on NN-2211 in the treatment for type 2 diabetes presented at the EASD meeting

Beneficial effects on beta-cell function reported for the new potassium channel opener NN-414

SAR on new series of selective bradycardic agents presented in Barcelona by Yamanouchi

Potent, orally active gastrin/CCK2 antagonists rationally designed at James Black Foundation

Pharmacological characterization of novel, selective beta3-adrenoceptor agonist from Kissei

LU-135252 does not attenuate ischemia/reperfusion-associated arrhythmia

Functional and structural improvement seen in CHF dogs treated with ivabradine

Novel human neutrophil elastase inhibitor effective in animal models of acute organ injury

IK-264 reduces body weight by suppressing appetite

Dusa reacquires rights to Levulan PDT

Pliva completes acquisition of Sidmak

Sequenom completes acquisition of Axiom Biotechnologies

Increase in weight associated with increased food consumption on olanzapine in mice

AGIX-4207 enters phase II in rheumatoid arthritis

New phase III study for anecortave acetate in AMD

Aricept sNDA submitted for vascular dementia

CRF antagonists and potential therapeutic uses reported in recent patent

Benzothiazepines from Banyu increase GLP-1

Novel mikanolide derivatives and their biological activity described by French researchers

Kinase inhibitors claimed for angiogenesis-related disorders

Telomerase inhibitors with utility in the treatment of cancer

Glucosylceramide synthase inhibitors with potential utility in polycystic kidney disease, etc.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...